Short answer: yes, for almost every age group. A progression rate of −1.00D per year is approximately 1.5–2× the mean rate for European children and well above the ~−0.50D/year rate commonly used in clinical practice to initiate or escalate myopia management. In axial length terms, it corresponds to roughly 0.30–0.40 mm of eye growth per year (depending on individual ocular biometry) — above the ~0.30 mm/year rate that population data suggest marks faster-than-average axial elongation. Context still matters: a 7-year-old growing at −1.00D/year is serious; a 15-year-old is unusual. The clinical significance is explored below.
To judge whether −1.00D per year is "fast," it must be benchmarked against population-level data. Published cohort studies and meta-analyses consistently report mean annual progression rates well below −1.00D for most age groups. A meta-analysis cited in the Singapore SCORM follow-up study found that urban European children (mean age 9.3 years) progress at a mean of −0.55D per year, while urban East Asian children of the same age progress at −0.82D per year in control arms of clinical trials.1
The U.S.-based COMET trial reported a mean annual progression of −0.59D per year among children aged 6–9 years assigned to single-vision lenses.2 A large French cohort study of 136,333 children aged 4–17 years found mean 12–24 month progression rates of −0.43D per year in the 7–9 age group and −0.42D per year in the 10–12 age group, with a clear deceleration into adolescence.3
Across these datasets, −1.00D per year sits well above the mean for every studied population. For European children, it represents nearly twice the average; for East Asian children, it is roughly 1.2× the average.
| Age group | Mean annual progression (D/yr) | Population / study | How 1 D/yr compares |
|---|---|---|---|
| 6–9 yrs | −0.59 D/yr | US COMET control arm2 | 1.7× the mean |
| ~9 yrs | −0.55 D/yr | Urban European (meta-analysis)1 | 1.8× the mean |
| ~9 yrs | −0.82 D/yr | Urban East Asian (meta-analysis)1 | 1.2× the mean |
| 7–9 yrs | −0.43 D/yr | French nationwide cohort (n=136,333)3 | 2.3× the mean |
| 10–12 yrs | −0.42 D/yr | French nationwide cohort3 | 2.4× the mean |
| All ages ≤12 yrs | −1.00 D/yr | The rate being evaluated | Fast — above average in all populations |
Prescription change in diopters is a functional measurement of blur. The structural parameter that drives long-term pathology risk is axial length — the physical elongation of the eye in millimetres. The relationship between diopters and axial length is not fixed: it varies with corneal curvature, lens power, and age. A range of approximately 0.30–0.40mm per diopter in school-aged children is widely cited as a working approximation in clinical reviews and optical modelling literature, including Bullimore & Brennan (2019).4,5
Applying this conversion: a progression rate of −1.00D per year corresponds to roughly 0.30–0.40mm of axial elongation per year, with the exact value depending on individual ocular biometry. Clinically, ~0.30mm/year of axial elongation is often used as a practical reference point for faster-than-average axial elongation, based on population normative data — though this figure represents a clinical convention rather than a formally defined guideline threshold, and the relevant norms vary by ethnicity and cohort.6 On this basis, a child progressing at −1.00D per year is likely at or above that marker across most studied populations.
A child gaining −1.00D per year will reach the structural thresholds associated with serious complications faster than their prescription change alone suggests. A −4.00D child with an axial length of 26.5mm carries meaningfully higher pathology risk than a −4.00D child with AL 24.5mm. Tracking axial length alongside refraction provides more accurate risk stratification.
Most published data on progression distribution use thresholds of ≥0.50D/year or ≥0.75D/year, because −1.00D/year sits at the tail of the distribution in most populations. In the French nationwide cohort, approximately 33% of children aged 7–9 years were in the faster-progressing subgroup (exceeding −0.50D per year) — indicating that −1.00D/year represents the upper portion of even that subgroup.3 The SCORM follow-up study from Singapore categorised "very fast" progression as faster than −1.25D per year; by extrapolation from that categorisation, −1.00D/year falls in the upper range of the "fast" category rather than the average.1
A retrospective study from Croatia found that children aged 7–9 years with both parents myopic had the fastest progression rates in that cohort at −0.69D per year — suggesting that even in the highest-risk European demographic studied, −1.00D/year would sit at the upper tail of the progression distribution.7
A commentary on rapid myopia progression notes that, with monotherapy (atropine 0.01%, DIMS lenses, or MiSight contact lenses), approximately 13–20% of children still progress by ≥0.75D in one year, with a smaller subset continuing at ≥1.00D.8 This figure comes from commentary literature synthesising multiple trials rather than a single primary study. It highlights a clinically relevant group — fast progressors who do not respond adequately to first-line treatment and may require combination therapy.
Eye growth decelerates predictably with age. The same −1.00D/year rate carries very different implications depending on when it occurs:
| Age at presentation | Context for −1.00 D/yr | Clinical interpretation |
|---|---|---|
| 6–8 years | ~1.7–2× the mean; early-onset window | Very fast. High lifetime accumulation expected if untreated. Treatment strongly indicated. |
| 9–11 years | ~1.7× the mean; peak accumulation period | Fast. The window where intervention has greatest cumulative benefit. Treatment strongly indicated. |
| 12–14 years | ~2.5–3× the mean for this age group | Very fast for age. Progression this rapid in early teens warrants immediate treatment review. |
| 15–17 years | Far above expected rate; approaching natural deceleration | Unusual. Should prompt investigation (cycloplegic refraction verification, AL measurement). Late-onset rapid progressors do exist. |
The Correction of Myopia Evaluation Trial (COMET) and SCORM data both confirm that younger age at myopia onset is independently associated with faster progression, higher final prescription, and greater risk of high myopia at teenage follow-up.2,9 In SCORM, each year younger at onset increased the odds of high myopia (SE ≤−5D) at age 11 by a factor of approximately 2.86.9
Progression does not continue indefinitely at its peak rate — it decelerates and typically stabilises in the late teens to early 20s. However, cumulative exposure is the key outcome: the total diopters accumulated by the time stabilisation occurs directly determines long-term structural risk.
The SCORM study found that every additional −0.3D per year increase in 3-year childhood SE progression was independently associated with −1.14D worse teenage spherical equivalent (p<0.001).10 A child progressing at −1.00D/year as opposed to −0.50D/year in the same cohort would be expected to arrive at teenage years significantly more myopic — a difference that compounds into meaningfully higher structural pathology risk in adulthood.
A child first diagnosed at −1.00D at age 8, progressing at −1.00D/year without treatment, would reach approximately −7.00D by age 14 and could approach −9.00D by stabilisation in the late teens — if that rate were sustained without the natural deceleration that typically occurs. In reality, progression is not constant: it tends to slow during adolescence. The same child progressing at the European average (−0.55D/year) would reach approximately −4.30D by age 14. The difference in likely final prescription remains clinically meaningful — a separation of multiple diopters that directly shifts structural complication risk.
Structural complications of myopia — myopic macular degeneration (MMD), retinal detachment, open-angle glaucoma, and cataract — arise from the mechanical stretching of ocular tissues as the eye elongates. Their risk rises non-linearly with increasing myopia. A systematic review and meta-analysis found that, compared to emmetropia or low myopia, high myopia (SE ≤−6.00D) is associated with:11
Tideman et al. (2016), analysing 15,693 Europeans, found that the cumulative risk of uncorrectable visual impairment by age 75 was approximately 39% for individuals with SE ≤−6.00D — compared to under 4% for those with AL 24–26mm.12 Every diopter that can be prevented through treatment is a diopter that reduces the probability of belonging to the high-risk group.
This is the foundation of the "each diopter matters" framing in modern myopia management: the goal of treatment is not cosmetic or functional vision correction — it is long-term ocular health.
In clinical practice, a rate of approximately −0.50D per year is widely used as a practical signal to initiate myopia management — alongside age, baseline refraction, and individual risk factors — and approximately −0.75D/year as a signal to escalate or switch modalities. These are convention-based values used across IMI-aligned practice — they reflect the lower bound of what published RCT control arms report as average rates, and are not hard numeric thresholds formally defined in IMI guidelines. A rate of −1.00D per year well exceeds both benchmarks, and in practice represents a child who should be under active treatment.
In the SCORM cohort data, first-year progression faster than −1.25D/year was associated with ongoing progression of −0.82D/year in subsequent years — the fastest-progressing sub-group.1 Children progressing at −1.00D/year, if untreated, are therefore likely to continue progressing rapidly, and are at elevated risk of crossing into high myopia before natural deceleration occurs.
This rate under monotherapy (atropine 0.01%, DIMS spectacle lens, or MiSight contact lens) should prompt a clinical review. The IMI 2025 recommends considering combination therapy for non-responders. Published evidence supports combining optical myopia control modalities with low-dose atropine in children who continue to progress rapidly despite single-modality treatment.
Enter age, current axial length, and prior axial length to calculate mm/year growth rate and compare to IMI 2025 age-matched norms. Free, no login.
Open the progression calculator →This page is for educational and clinical reference purposes and does not constitute medical advice. MyopiaTracker is a research and educational visualization platform — not a diagnostic device or medical device. Treatment availability and regulatory approval vary by country. Consult a qualified optometrist or ophthalmologist for personalised clinical decisions. MiSight® is a registered trademark of The Cooper Companies. Stellest® is a registered trademark of Essilor International.